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Lowering low-density lipoprotein (LDL-C) and triglyceride (TG) levels form the cornerstone approach of 
cardiovascular risk reduction, and a higher high-density lipoprotein (HDL-C) is thought to be protective. 
However, in acute myocardial infarction (AMI) patients, higher admission LDL-C and TG levels have 
been shown to be associated with better clinical outcomes - termed the ‘lipid paradox’. We studied the 
relationship between lipid profile obtained within 72 hours of presentation, and all-cause mortality 
(during hospitalization, at 30-days and 12-months), and rehospitalization for heart failure and non-
fatal AMI at 12-months in ST-segment elevation myocardial infarction (STEMI) and non-ST-segment 
elevation myocardial infarction (NSTEMI) patients treated by percutaneous coronary intervention 
(PCI). We included 11543 STEMI and 8470 NSTEMI patients who underwent PCI in the Singapore 
Myocardial Infarction Registry between 2008–2015. NSTEMI patients were older (60.3 years vs 57.7 
years, p < 0.001) and more likely to be female (22.4% vs 15.0%, p < 0.001). In NSTEMI, a lower LDL-C 
was paradoxically associated with worse outcomes for death during hospitalization, within 30-days 
and within 12-months (all p < 0.001), but adjustment eliminated this paradox. In contrast, the paradox 
for LDL-C persisted for all primary outcomes after adjustment in STEMI. For NSTEMI patients, a lower 
HDL-C was associated with a higher risk of death during hospitalization but in STEMI patients a lower 
HDL-C was paradoxically associated with a lower risk of death during hospitalization. For this endpoint, 
the interaction term for HDL-C and type of MI was significant even after adjustment. An elevated TG 
level was not protective after adjustment. These observations may be due to differing characteristics 
and underlying pathophysiological mechanisms in NSTEMI and STEMI.
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Acute myocardial infarction (AMI) and the heart failure which often follows are among the leading causes of 
death and disability worldwide1. Elevated levels of low-density lipoprotein (LDL-C) and triglycerides (TG) are 
well-established risk factors for developing AMI2–4. Circulating LDL-C enters the endothelium of arterial walls 
resulting in inflammation and formation of atherosclerotic plaques, which on rupturing,result in AMI3. Similarly, 
elevated TG levels are known to cause premature atherosclerosis5. Pharmacological lowering of LDL-C and TG 
levels can prevent atherosclerotic disease and subsequent AMI6. Although, a low level of high-density lipoprotein 
cholesterol (HDL-C) is a known risk factor for the development of AMI7, pharmacological treatments aimed at 
elevating HDL-C levels have not been shown to improve clinical outcomes8.
Despite these well-established associations, some studies have described the existence of a ‘lipid paradox’ in 
AMI patients. These patients paradoxically have better outcomes despite having higher LDL-C and TG levels 
at time of admission. Previous studies have studied the lipid paradox in AMI patients, but did not specifically 
examine the phenomenon of the lipid paradox between non-ST elevation myocardial infarction (NSTEMI) and 
STEMI9–13. While there are some similarities between the pathophysiology underlying STEMI and NSTEMI pop-
ulations14, STEMI populations have been found to have an increased pro-inflammatory state and a different 
serological profile compared to NSTEMI patients15–17.
We hypothesize that there are differences in the lipid paradox between STEMI and NSTEMI patients and this 
may be attributed to the differences in underlying pathophysiology between the 2 entities. As such, we conducted 
this study to clarify the relationship of the lipid paradox and clinical outcomes amongst STEMI and NSTEMI 
patients who have had percutaneous coronary intervention (PCI) using a nationwide AMI registry.
Methods
We conducted a retrospective observational analysis of patients with AMI from our national registry, The 
Singapore Myocardial Infarction Registry (SMIR). This registry is managed by the National Registry of Diseases 
Office and collects epidemiological and clinical data on all AMI cases diagnosed in all public and private sector 
hospitals and a small number of out-of-hospital AMI deaths certified by medical practitioners in Singapore18–20. 
Notification of AMI to the registry has been mandated by the National Registry of Diseases Act enacted in 2012. 
Public sector cases comprised 98% of the registered cases. Registry data were received from various sources 
and were processed to obtain unique cases. The sources of data included patient medical claim listings, hospital 
in-patient discharge summaries, cardiac biomarker listings from hospital laboratories and the national death 
registry. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 
410 was used to identify AMI cases diagnosed prior to 2012 while ICD-10 (Australian Modification) codes I21 
and I22 were used for AMI cases diagnosed in 2012. The differentiation between STEMI and NSTEMI was based 
on presenting symptoms, cardiac biomarkers and ECG assessment, and aligned with clinician’s diagnosis doc-
umented in the physical case notes and electronic medical records. STEMI was defined as follows: typical chest 
pain of 20 minutes and significant ST-segment elevation (0.1 or 0.2 mV on 2 adjacent limb or precordial leads, 
respectively, or new left bundle-branch block) and confirmed subsequently by a rise in biomarkers. All ECGs 
were interpreted, and all diagnoses were adjudicated centrally at the National Registry of Diseases Office. The 
multinational monitoring of trends and determinants in cardiovascular disease (MONICA) criteriawere used 
for defining episodes. Detailed patient data were extracted from clinical medicalrecords including Emergency 
department notes, clinical charts, and discharge summaries, by dedicated registry coordinators from the SMIR. 
Yearly audits on data collected were done to ensure data accuracy and inter-rater reliability. Logic checks were 
done and illogical or outlier data were highlighted for review.
This study was based onAMI cases reported to the SMIR from 1st January 2008 onwards who had PCI. Patients 
without PCI were excluded as we wanted to study those patients with a Type 1 myocardial infarction21.
The exposure of interest was lipid profile obtained within 72 hours of the AMI (LDL-C, Total cholesterol 
[TC]; high-density lipoprotein [HDL-C]; TG). The lipid profile was analyzed in both numeric and categor-
ical form. Lipids were categorized based on local guidelines22. LDL-C levels were divided into optimal (1.8–
2.5 mmol/L), desirable (2.6–3.3 mmol/L), borderline high (3.4–4.0 mmol/L), high (4.1–4.8 mmol/L) and very 
high (≥4.9 mmol/L) levels; TC levels into desirable (<5.2 mmol/L), borderline high (5.2–6.1 mmol/L) and 
high (≥6.2 mmol/L) levels; HDL-C levels into low (<1.0 mmol/L), desirable (1.0–1.5 mmol/L) and optimal 
(≥1.6 mmol/L) levels; TG levels into optimal (<1.7 mmol/L), desirable (1.7–2.2 mmol/L), high (2.3–4.4 mmol/L) 
and very high (≥4.5 mmol/L) levels. A stricter cut-off of 1.8 mmol/L for LDL-C was used in line with interna-
tional guidelines as there was the most evidence for risk modification by lowering LDL-C compared to the other 
cholesterol fractions23,24. Primary outcomes of interest were all-cause mortality during hospitalization, within 
30-day and within 12 months. As the mortality data, obtained from the Death Registry of Ministry of Home 
Affairs, was available until 2016 at the point of analysis, findings on primary outcomes were based on AMI cases 
with onset in 2008 to 2015. Secondary outcomes were rehospitalization within 12 months for heart failure (HF)
andAMI for patients that were discharged alive. As the rehospitalization data, obtained from the final discharge 
diagnosis registered with the national financial claims database of Ministry of Health, was available until 2014 at 
the point of analysis, findings on secondary outcomes were based on AMI cases with onset in 2008 to 2013. No 
patient was lost to follow-up as it is mandatory for all deaths to be registered within 24 hours of occurrence25 and 
the national financial claims database covers all public and private healthcare institutions.
We analyzed the AMI cases as a whole and had comparison groups comprising STEMI and NSTEMI patients. 
Numeric variables were expressed as median and interquartile range, while categorical variables were expressed 
as frequency and percentages. Comparison between STEMI and NSTEMI patients was done using Wilcoxon 
rank sum test for numeric variables and Chi-square test for categorical variables. Cox regression was used to esti-
mate the risk of death during hospitalization, death within 30 days of AMI onset and death within 1 year of AMI 
onset. Coxregressionadjusted for the competing risk from death was used to estimate the risk of hospitalization 
for HF and AMI within 1 year from AMI discharge. Multivariable models were adjusted for whether patient was 
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on oral medication for hyperlipidemia, age, sex, race, body mass index, history of diabetes, history of hyperten-
sion, smoking status, history of AMI/coronary artery bypass grafting (CABG)/PCI, Killip class on admission, 
presence of cardiopulmonary resuscitation (CPR) in ambulance, random blood glucose levels within 72 hours of 
onset of AMI, admission creatinine, admission haemoglobin, presence of elevated first troponin within 72 hours 
from AMI onset, left ventricular ejection fraction (LVEF) of <50% during hospitalization, presence of anterior 
myocardial infarction (for STEMI only), and symptom-to-balloon time (for STEMI only). These variables were 
selected to be included in the multivariable models as they were statistically different across the categories of 
lipids and they were clinically associated with the outcomes of interest. We performed further analyses to study 
the interaction between the type of MI (STEMI/NSTEMI) and lipids in relation to the primary and secondary 
outcomes. Supplementary Fig. 1 shows the patient selection criteria. A sensitivity analysis for missing data was 
also performed. This was done using multiple imputation with 20 imputed datasets and no auxiliary variables 
based on the Markov Chain Monte Carlo procedure assuming all variables in the model having a joint multi-
variate normal distribution. Sensitivity analysis showed that the results were in the similar direction albeit with 
differing magnitudes and statistical significance. As such, we opted to maintain the data in its original form and 
missing data were dropped from analyses through case deletion without any imputation.
The institutional review board granted an exemption for conducting this study without need for informed con-
sent (SingHealth Centralised Institutional Review Board Reference No: 2016/2480) as this study involved analysis 
of a dataset without identifiers. The research was conducted in accordance with the Declaration of Helsinki. The 
statistician had access to anonymizedindividual data points while the other co-authors had access to analyzed, 
aggregated data. Statistical analysis was performed using Stata SE Version 13 (StataCorp. 2013. Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP). All reported p-values were 2-sided and p-values < 0.05 
were considered to be statistically significant.
Results
The final patient population comprised 20013 patients. There were 11543 STEMI patients and 8470 NSTEMI 
patients available for analysis. Patient characteristics are shown in Table 1. STEMI patients were about 2 years 
younger than NSTEMI patients and more likely to be male. Fewer STEMI patients had a prior history of dia-
betes mellitus, hypertension, history of AMI/CABG/PCI but they were more likely to be smokers. In terms of 
cholesterol levels, STEMI patients had a higher LDL-C (3.4 mmol/l vs 3.2 mmol/l, p < 0.001), lower TG levels 
(1.4 mmol/l vs 1.6 mmol/l, p < 0.001) but there was no difference in HDL-C levels. There were a higher proportion 
of STEMI patients than NSTEMI patients with higher TC. STEMI patients were less likely to be on oral medica-
tions for hyperlipidemia prior to presentation (62.6% vs 75.1%, p < 0.001). STEMI patients were also more likely 
to have a depressed ejection fraction (61.2% vs 39.6%, p < 0.001).
AMI Population. Firstly, we analyzed the entire AMI population. Higher LDL-C levels were associated with 
a lower risk of death during hospitalization, at 30 days and at 1 year on both unadjusted and adjusted analysis 
(Table 2) but not for rehospitalization for heart failure or myocardial infarction within 1 year from discharge. 
While there was a similar association for TG levels for the risk of death, this did not persist after adjustment 
(Supplementary Table 1). There was an association between higher TC levels with worse primary outcomes 
on unadjusted and adjusted analysis for the primary outcomes but not for the secondary outcomes of interest 
(Supplementary Table 2). After adjustment, there was actually a higher risk of death at 30-days and at 1-year with 
HDL-C levels of <1.0 mmol/L which suggest that there was no paradox present for HDL-C levels for the entire 
AMI population (Supplementary Table 3).
STEMI Patients. We next examined the correlations of lipid levels with the primary and secondary out-
comes, for both STEMI and NSTEMI patients. Of note, in terms of primary outcomes for STEMI patients, a 
higher LDL-C was inversely correlated with a lower risk of death during hospitalization, at 30 days and at 1 
year on both unadjusted and adjusted analyses (Figs. 1 to 6 and Supplementary Table 4). In terms of secondary 
outcomes for STEMI patients on unadjusted analysis, a higher LDL-C was similarly inversely correlated with a 
lower risk of rehospitalization for HF and AMI within 1 year from hospitalization discharge. After adjustment, 
the observed lipid paradox for the secondary outcomes of HF and AMI hospitalizations within 1 year from AMI 
discharge and higher LDL-C levels was no longer present. The significant variables after adjustment for HF hos-
pitalizations were use of oral medications for hyperlipidemia, older age, Malay and Indian ethnicities, history of 
diabetes mellitus, history of hypertension, history of AMI/CABG/PCI, higher Killip class on admission, elevated 
troponin levels, longer symptom-to-balloon time and depressed LVEF. The significant variables after adjustment 
for AMI hospitalizations were driven by female sex, Malay, Indian and other ethnicities, smoking status and his-
tory of AMI/CABG/PCI. There was a similar relationship between a lower LDL-C and worse secondary outcomes 
for hospitalization for HF and AMI on unadjusted analysis but these correlations did not exist after adjustment 
(Supplementary Table 4).
There was an association between higher TC levels with worse primary outcomes on unadjusted and adjusted 
analysis for the primary outcomes but not for the secondary outcomes of interest (Supplementary Table 5).
For HDL-C, there was an association between lower HDL-C levels and better primary outcomes on unad-
justed analysis but only the primary outcome of death during hospitalization persisted after adjustment. There 
was no such correlation for the secondary outcomes (Table 3). For TG, there was no strong association between 
TG levels and primary or secondary outcomes (Supplementary Table 6).
NSTEMI Patients. There was an inverse correlation between LDL-C levels and the primary outcomes of risk 
of death during hospitalization, at 30 days and at 1 year as well as the secondary outcomes of rehospitalization 
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STEMI (n = 11543) NSTEMI (n = 8470) p
Age in years, median (IQR) 57.7 (50.7–66.0) 60.3 (52.5–69.4) <0.001
Sex, n (%)
Male 9810 (85.0) 6570 (77.6)
<0.001
Female 1733 (15.0) 1900 (22.4)
Race, n (%)
Chinese 7125 (61.7) 5253 (62.0)
0.004
Malay 2343 (20.3) 1575 (18.6)
Indian 1874 (16.2) 1499 (17.7)
Others 201 (1.7) 143 (1.7)
History of diabetes, n (%)
Yes 3252 (28.2) 3312 (39.1)
<0.001
No 8285 (71.8) 5156 (60.9)
History of hypertension, n (%)
Yes 6014 (52.1) 5730 (67.7)
<0.001
No 5523 (47.9) 2739 (32.3)
Smoking, n (%)
Never 4203 (36.8) 3689 (43.7)
<0.001Former 1571 (13.8) 1657 (19.6)
Current 5640 (49.4) 3093 (36.7)
History of AMI/CABG/PCI, n (%)
Yes 1744 (15.1) 2733 (32.3)
<0.001
No 9797 (84.9) 5737 (67.7)
BMI in kg/m2, median (IQR) 24.6 (22.3–27.3) 24.9 (22.6–27.9) <0.001
Killip class on admission, n (%)
I 9549 (82.7) 7061 (83.4)
<0.001
II 543 (4.7) 805 (9.5)
III 436 (3.8) 495 (5.8)
IV 1014 (8.8) 107 (1.3)
CPR in ambulance/ED, n (%)
Yes 474 (4.1) 50 (0.6)
<0.001
No 11069 (95.9) 8420 (99.4)




LDL-C in mmol/l within 72 h from MI onset
Numeric value, median (IQR) 3.4 (2.6–4.1) 3.2 (2.4–4.0) <0.001
Ordinal categories, n (%)
<1.8 707 (6.8) 652 (9.2)
<0.001
1.8–2.5 1881 (18.1) 1598 (22.6)
2.6–3.3 2719 (26.1) 1771 (25.1)
3.4–4.0 2491 (23.9) 1418 (20.1)
4.1–4.8 1623 (15.6) 970 (13.7)
≥4.9 1002 (9.6) 653 (9.2)
TC in mmol/lwithin 72 h from MI onset
Numeric value, median (IQR) 5.1 (4.3–6.0) 5.0 (4.1–5.9) <0.001
Ordinal categories, n (%)
<5.2 5768 (54.2) 4153 (57.3)
<0.0015.2–6.1 2854 (26.8) 1697 (23.4)
≥6.2 2026 (19.0) 1397 (19.3)
HDL-C in mmol/l within 72 h from MI onset
Numeric value, median (IQR) 1.0 (0.9–1.2) 1.0 (0.9–1.2) 0.261
Ordinal categories, n (%)
≥1.6 510 (4.8) 363 (5.0)
0.0561.0–1.5 5275 (49.5) 3455 (47.7)
<1.0 4874 (45.7) 3430 (47.3)
TG in mmol/l within 72 h from MI onset
Continued
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for heart failure and myocardial infarction within 1 year on unadjusted analysis for NSTEMI patients but was not 
present after adjustment (Supplementary Table 7).
There was an inverse relationship between the primary outcomes and TC levels and the secondary outcomes of 
rehospitalization for HF and AMI, but these correlations did not exist after adjustment (Supplementary Table 8). 
Lower HDL-C levels appeared to increase the risk of death during hospitalization after adjustment in contrast to 
the trend demonstrated in STEMI patients (Table 4). There was no correlation between TG levels and primary 
and secondary outcomes (Supplementary Table 9).
Interaction between type of myocardial infarction and lipids. Further analyses for interaction 
between the type of MI and lipids demonstrated a significant interaction term after adjustment for HDL-C only 
for the outcome for death during hospitalization (p = 0.015) (Table 5). There was no significant interaction after 
adjustment for all other outcomes and lipid levels.
Discussion
Our main study findings were as follows: 1. The lipid paradox for LDL-C exists for STEMI patients undergoing 
PCI for the primary outcomes of death during hospitalization, at 30 days and at 1 year, but not for NSTEMI 
patients i.e. a pseudo-paradox was present for NSTEMI patients; 2. The lipid paradox for TG levels for STEMI 
patients undergoing PCI did not exist in our study after adjustment i.e. a pseudo-paradox is present; 3. HDL-C 
levels trended towards a paradox for STEMI patients but not for NSTEMI patients, and there was significant 
interaction between the type of MI and HDL-C levels for the outcome of death during hospitalization.
A number of studies have investigated the lipid paradox in patients with acute coronary syndromes. These 
studies were done in acute coronary syndrome populations that involved STEMI and NSTEMI populations 
as a whole, but did not specifically compare between these 2 groups11,13,26–28. Cho et al. studied a population 
of AMI patients post-PCI in relation to 30-day and 1-year outcomes, but did not stratify between the STEMI 
and NSTEMI groups. In their study, they found that patients with higher LDL-C levels, except for patients with 
LDL-C > 160 mg/dL (>4.1 mmol/L), were related to better outcomes. However, they reported independent pre-
dictive factors of 12-month mortality being age, systolic blood pressure, acute myocardial infarction, LVEF, renal 
function, Killip class, N-terminal-pro-B-type natriuretic level and use of renin-angiotensin receptor blockers 
(RAB) use, and concluded that their observation was an apparent paradox due to confounding factors. In our 
study, we accounted for the above variables (except for biomarker and RAB use) and demonstrated that the lipid 
paradox persisted in the STEMI but not the NSTEMI population. Interestingly, while we did not account for RAB 
use, the duration required for RAB use to effect positive myocardial remodeling in post-AMI patients would 
require time29. We observed the lipid paradox being present even for LDL-C in STEMI patients during the index 
STEMI (n = 11543) NSTEMI (n = 8470) p
Numeric value, median (IQR) 1.4 (1.0–2.0) 1.6 (1.1–2.3) <0.001
Ordinal categories, n (%)
<1.7 6917 (65.1) 4020 (55.8)
<0.001
1.7–2.2 1874 (17.6) 1496 (20.8)
2.3–4.4 1543 (14.5) 1442 (20.0)
≥4.5 289 (2.7) 247 (3.4)
Oral medication for hyperlipidemia, n (%)
Yes 3315 (62.6) 4093 (75.1) <0.001
No 1983 (37.4) 1359 (24.9)
Not applicable 6235 3017
Random glucose in mmol/L within 72 h from MI onset, median (IQR) 9.1 (7.2–13.2) 8.2 (6.3–12.5) <0.001
Serum creatinine in 10µmol on admission, median (IQR) 9.0 (7.7–10.9) 8.6 (7.3–10.8) <0.001
Haemoglobin in g/dL on admission, median (IQR) 14.6 (13.4–15.7) 14.0 (12.6–15.2) <0.001
Elevated first troponin within 72 h from MI onset, n (%)
Yes 5585 (49.3) 4655 (55.5)
<0.001
No 5745 (50.7) 3730 (44.4)
Symptom-to-balloon time in minutes, median (IQR) 182 (119–307) Not applicable
Days from MI onset to PCI, median (IQR) 0 (0–0) 2 (1–4) <0.001
LVEF < 50% during hospitalization, n (%)
Yes 6610 (61.2) 2742 (39.6)
<0.001
No 4195 (38.8) 4176 (60.4)
Days from MI onset to discharge, median (IQR) 4 (3–5) 4 (3–6) <0.001
Table 1. Characteristics of ST elevation (STEMI) and non-ST elevation myocardial infarction (NSTEMI) 
patients in the study. Abbreviations: AMI, acute myocardial infarction; BMI, body mass index; CPR, 
cardiopulmonary resuscitation; CABG, coronary artery bypass grafting; ED, emergency department; HDL-
C, high density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low density lipoprotein cholesterol; 
LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; TC, total cholesterol; TG, 
triglycerides.
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hospitalization for myocardial infarction, which would not have been a sufficient duration of time for RABs to 
exert their myocardial remodeling effects. As such, we believe that RAB use, while prognostically useful in the 
long-term, would not explain our short-term observation.
For triglyceride levels in ACS patients, Cheng et al. studied a cohort of STEMI patients who received primary 
PCI in a single tertiary referral hospital and found that the serum triglyceride level had an inverse relationship 
with in-hospital death and late outcomes30. They postulate that higher TG levels may have a role in infarct size 
stabilization, reducing the risk of arrhythmias. An alternative postulated explanation is that TG actually reflects 
nutritional status and a lower TG means that the body’s nutritional state is poorer and hence may halt the patient’s 
All STEMI + NSTEMI patients All STEMI + NSTEMI patients discharged alive
Death during 
hospitalization
Death within 30 days from 
MI onset
Death within 1 year from 
MI onset
Rehospitalization for 
HF within 1 year from 
MI discharge
Rehospitalization for 
MI within 1 year from 
MI discharge
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Unadjusted
LDL-C in mmol/l 0.77 (0.74–0.80) <0.001 0.65 (0.62–0.68) <0.001 0.68 (0.66–0.70) <0.001 0.97 (0.90–1.04) 0.411 0.95 (0.89–1.03) 0.220
Ordinal categories
<1.8 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
1.8–2.5 0.68 (0.60–0.78) <0.001 0.52 (0.46–0.58) <0.001 0.58 (0.53–0.62) <0.001 0.90 (0.68–1.19) 0.451 1.05 (0.76–1.44) 0.783
2.6–3.3 0.56 (0.49–0.65) <0.001 0.37 (0.32–0.42) <0.001 0.40 (0.36–0.44) <0.001 0.95 (0.72–1.25) 0.719 1.04 (0.76–1.42) 0.821
3.4–4.0 0.45 (0.38–0.53) <0.001 0.26 (0.22–0.30) <0.001 0.29 (0.26–0.32) <0.001 0.76 (0.56–1.03) 0.078 0.86 (0.61–1.22) 0.402
4.1–4.8 0.47 (0.38–0.58) <0.001 0.25 (0.21–0.31) <0.001 0.26 (0.23–0.30) <0.001 0.77 (0.55–1.08) 0.130 0.89 (0.61–1.30) 0.553
≥4.9 0.37 (0.29–0.48) <0.001 0.22 (0.15–0.33) <0.001 0.32 (0.28–0.37) <0.001 0.95 (0.66–1.36) 0.775 0.88 (0.57–1.34) 0.543
Adjusted*
LDL in mmol/l 0.81 (0.76–0.87) <0.001 0.79 (0.74–0.85) <0.001 0.88 (0.84–0.91) <0.001 1.01 (0.93–1.10) 0.795 0.98 (0.88–1.08) 0.640
Ordinal categories
<1.8 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
1.8–2.5 0.72 (0.60–0.86) <0.001 0.62 (0.52–0.73) <0.001 0.77 (0.68–0.86) <0.001 0.83 (0.59–1.16) 0.281 1.14 (0.76–1.70) 0.519
2.6–3.3 0.62 (0.50–0.76) <0.001 0.54 (0.44–0.66) <0.001 0.66 (0.58–0.76) <0.001 0.97 (0.69–1.36) 0.854 1.32 (0.87–2.01) 0.190
3.4–4.0 0.56 (0.43–0.72) <0.001 0.46 (0.36–0.59) <0.001 0.63 (0.53–0.73) <0.001 0.95 (0.65–1.40) 0.801 1.01 (0.63–1.61) 0.968
4.1–4.8 0.60 (0.43–0.82) 0.002 0.53 (0.40–0.70) <0.001 0.66 (0.55–0.80) <0.001 0.82 (0.53–1.27) 0.381 1.03 (0.62–1.73) 0.899
≥4.9 0.48 (0.34–0.70) <0.001 0.45 (0.32–0.63) <0.001 0.68 (0.55–0.85) <0.001 1.12 (0.71–1.76) 0.638 1.03 (0.57–1.84) 0.930
Table 2. Unadjusted and adjusted analysis examining the correlations between low density lipoprotein 
cholesterol levels and the primary and secondary outcomes in ST elevation myocardial infarction (STEMI) 
and Non-ST elevation myocardial infarction (NSTEMI) patients who underwent percutaneous coronary 
intervention. *Adjusted for: oral medication for hyperlipidemia (yes/no/not applicable), age (numeric), sex 
(male/female), race (chinese/malay/indian/others), history of diabetes (yes/no), history of hypertension (yes/
no), smoking status (never/former/current), history of AMI/CABG/PTCA (yes/no), BMI (numeric), Killip 
class on admission (1/2/3/4), CPR in ambulance/ED (yes/no), random blood glucose within 72 h from onset 
(numeric), creatinine on admission (numeric), haemoglobin on admission (numeric), elevated first troponin 
within 72 h from MI onset (yes/no), left ventricular ejection fraction <50% during hospitalization (yes/no).
Figure 1. Forrest plots showing adjusted odds ratio of death during hospitalization across different LDL-C 
levels for patients with ST-elevation myocardial infarction (STEMI) and non ST-elevation myocardial infarction 
(NSTEMI).
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recovery from STEMI. We did not find the same results in our study cohort after adjustment, nor was there any 
major differences between STEMI or NSTEMI groups for TG levels. A possible explanation is that our study 
adjusted for more variables compared to the study by Cheng et al., and there might be an apparent paradox for TG 
in that study due to residual confounding.
Figure 3. Forrest plots showing adjusted odds ratio of death within 1 year from MI onset across different 
LDL-C levels for patients with ST-elevation myocardial infarction (STEMI) and non ST-elevation myocardial 
infarction (NSTEMI).
Figure 2. Forrest plots showing adjusted odds ratio of death within 30 days of myocardial infarction (MI) 
onset across different LDL-C levels for patients with ST-elevation myocardial infarction (STEMI) and non ST-
elevation myocardial infarction (NSTEMI).
Figure 4. Restricted cubic spline showing the relationship between LDL-C levels for patients with ST-elevation 
myocardial infarction (STEMI) and non ST-elevation myocardial infarction (NSTEMI) and the relative hazard 
for death during hospitalization (A), at 30-days (B) and at 1-year (C) from MI.
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STEMI patients have been described to have an increased pro-inflammatory state compared to NSTEMI 
patients15,31. Our study also supports the role of inflammation as the underlying factor in the lipid paradox, as we 
demonstrated a lipid paradox in STEMI patients but not NSTEMI patients. Furthermore, this may be contributed 
by the fact that the STEMI and NSTEMI patients have different clinical characteristics. STEMI patients in our 
population were more likely to be smokers – the latter contributes to a pro-inflammatory state32. A counterpoint 
to this argument would be that the subjects in our STEMI population were more likely to be on oral medications 
for hyperlipidemia, and it is known that statins exert a pleiotropic anti-inflammatory effect33. Statins result in 
lower TC, LDL-C and TG levels34. A study demonstrated the effect of statins on outcome modification in patients 
with low LDL-C levels. Oduncu et al. demonstratedthat patients with statin-induced low LDL-C on admis-
sion had better outcomes in STEMI and predict lower mortality, but patients with spontaneously low LDL-C 
without statin treatment predict higher mortality35. Similarly, they postulate that statin exert an anticoagulant, 
anti-platelet and anti-inflammatory effect. Those with spontaneously low LDL-C in their study were associated 
with increased inflammation as reflected by higher inflammatory markers (leukocyte count, neutrophil/lympho-
cyte ratio and C-reactive protein levels)35.
Building on this, with regards to HDL-C, patients with a lower HDL-C trended towards better outcomes for 
STEMI patients (HDL-C lipid paradox). On the contrary, a lower HDL-C trended towards worse outcomes for 
NSTEMI patients, although this was only statistically significant for death during hospitalization at a level of 
HDL-C between 1.0–1.5 mmol/L. Previous studies in AMI populations have demonstrated that a lower HDL-C 
leads to greater mortality in both STEMI36 and NSTEMI patients37. This observation may be due to the possibility 
of the presence of dysfunctional HDL-C, which has been described to be present in patients with coronary artery 
disease, obesity, diabetes mellitus and smokers38. It is increasingly recognized that the function and subclass of 
HDL-C needs to be considered above the plasma concentrations, as plasma concentrations alone cannot account 
for the epidemiological observations and lack of treatment efficacy when raising HDL-C levels39–41. Dysfunctional 
HDL-C has a reduced pro-oxidative effect and increased pro-inflammatory effect. NSTEMI and STEMI patients 
have different levels of inflammation present, and this difference in inflammatory process can modify HDL-C 
functionality41, thus potentially leading to the observations in our study. Also, STEMI patients in our population 
Figure 5. Restricted cubic spline showing the relationship between LDL-C levels for patients with ST-elevation 
myocardial infarction (STEMI) and non ST-elevation myocardial infarction (NSTEMI) and the relative hazard 
for death at 30-days from MI.
Figure 6. Restricted cubic spline showing the relationship between LDL-C levels for patients with ST-elevation 
myocardial infarction (STEMI) and non ST-elevation myocardial infarction (NSTEMI) and the relative hazard 
for death at 1-year from MI.
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were less likely to have a history of AMI/CABG/PCI (a surrogate for CAD), have a lower body mass index and less 
diabetes mellitus although there were a higher proportion of smokers compared to NSTEMI. This difference in 
baseline characteristics may also account for differing levels of dysfunctional HDL-C and hence a better outcome 
in STEMI patients. Further study of HDL-C function and subfractionsin addition to levels in this population 
would be helpful in the future in understanding this observation. Unfortunately, we did not have information 
on inflammatory markers in our population including C-reactive protein and total white cell count, nor did we 
have compliance data to statin use and could not specifically examine inflammation as a factor, but this can be the 
focus of future studies.
There have been other studies performed to examine the lipid paradox in cardiac patients in non-MI settings. 
Authors have described the potential pathophysiological mechanisms of a low LDL-C in situations of increased 
inflammation such as in heart failure. They explain that increased intestinal edema leads to an increase in translo-
cation of bacterial lipoprotein saccharides (LPS) from the intestines into the blood, which induces inflammatory 
markers such as tumour necrosis factor-alpha. Lipoproteins form micelles around the bacterial LPS to inactivate 
the bacterial components, hence accounting for lower LDL-C levels42,43. While our study did not examine the 
biological mechanisms of the lipid paradox in post-MI PCI patients, gut bacteria have been linked to myocardial 
infarction and this could be a postulated mechanism of action44. Further potential explanations for the lipid para-
dox in heart failure patients include statin pre-medication as well as poorer nutritional status43, which wasafactor 
we adjusted for in our study.
The lipid paradox has also been described in non-cardiac conditions. Amezaga Urruela et al. described active 
rheumatoid arthritis patients having lower lipid levels, and postulated that this may be due to an inflammatory 
process45. A similar inflammatory cytokine release is observed in acute pancreatitis in which the lipid paradox 
has also been observed46. The inflammatory hypothesis is postulated to contribute significantly to the under-
lying pathophysiology of AMI47; this inflammatory hypothesis has recently been reinforced in the landmark 
Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial which studied the use of the 
orphan drug canakinumab to reduce the risk of developing cardiovascular events using anti-inflammatory ther-
apy with interleukin-1β inhibition48.
Finally, it might be prudent for clinicians not to be unduly influenced by the low measured LDL-C levels and 
hence withhold essential statin treatment for patients with acute myocardial infarction. This warning has been 
mentioned previously for nephrology patients in which the authors argue that despite the presence of the lipid 
paradox, statins exert an anti-inflammatory pleotropic effect which makes them effective medications for cardi-
ovascular risk reduction49. This is supported by the American and European lipid management guidelines which 
advocate for the use of high intensity statins in AMI patients regardless of LDL-C levels23,24.
Strengths and limitations. To the best of our knowledge, this is the largest study examining the lipid 
paradox in an unselected population of patients that are post-MI and have undergone PCI. Our study does have 
some limitations. As this is a cross-sectional analysis of registry data, we could demonstrate associations but not 
causation. The SMIR did not collect data on liver function tests as hepatic dysfunction is one of the postulated 
All STEMI patients All STEMI patients discharged alive
Death during 
hospitalization
Death within 30 days from 
MI onset
Death within 1 year from 
MI onset
Rehospitalization for 
HF within 1 year from 
MI discharge
Rehospitalization for 
MI within 1 year from 
MI discharge
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Unadjusted
HDL-C in mmol/l 1.17 (0.89–1.53) 0.264 1.13 (0.87–1.47) 0.356 1.24 (1.03–1.50) 0.020 1.09 (0.80–1.48) 0.576 1.09 (0.75–1.58) 0.638
Ordinal categories
>=1.6 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
1.0–1.5 0.46 (0.33–0.64) <0.001 0.41 (0.30–0.58) <0.001 0.40 (0.31–0.52) <0.001 0.69 (0.44–1.09) 0.110 0.83 (0.46–1.51) 0.543
<1.0 0.55 (0.39–0.76) <0.001 0.52 (0.37–0.72) <0.001 0.46 (0.36–0.60) <0.001 0.67 (0.43–1.06) 0.085 0.79 (0.43–1.43) 0.430
Adjusted*
HDL-C in mmol/l 1.22 (0.86–1.73) 0.274 0.94 (0.62–1.42) 0.760 1.03 (0.76–1.38) 0.865 0.87 (0.56–1.37) 0.552 1.12 (0.73–1.70) 0.614
Ordinal categories
>=1.6 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
1.0–1.5 0.55 (0.34–0.87) 0.011 0.53 (0.34–0.84) 0.007 0.56 (0.39–0.79) 0.001 0.79 (0.42–1.47) 0.449 1.34 (0.54–3.30) 0.530
<1.0 0.64 (0.40–1.04) 0.072 0.77 (0.48–1.24) 0.285 0.74 (0.52–1.06) 0.103 0.94 (0.50–1.78) 0.856 1.18 (0.47–2.96) 0.727
Table 3. Unadjusted and adjusted analysis examining the correlations between high density lipoprotein 
cholesterol levels and the primary and secondary outcomes in ST elevation myocardial infarction patients who 
underwent percutaneous coronary intervention. *Adjusted for: oral medication for hyperlipidemia (yes/no/
not applicable), age (numeric), sex (male/female), race (chinese/malay/indian/others), history of diabetes (yes/
no), history of hypertension (yes/no), smoking status (never/former/current), history of AMI/CABG/PTCA 
(yes/no), BMI (numeric), Killip class on admission (1/2/3/4), CPR in ambulance/ED (yes/no), random blood 
glucose within 72 h from onset (numeric), creatinine on admission (numeric), haemoglobin on admission 
(numeric), elevated first troponin within 72 h from MI onset (yes/no), left ventricular ejection fraction <50% 
during hospitalization (yes/no), anterior MI (yes/no), symptom-to-balloon time (numeric).
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reasons accounting for the lipid paradox for LDL-C. Nevertheless, we did have information on Killip class and 
used this as a surrogate for predicting the possibility of liver failure. The SMIR did not collect data on biomarker 
levels such as brain-natriuretic peptide, specific subfractions and functionality testing of HDL-C, information on 
doses of in-hospital or pre-hospital statin use, nor did it collect PCI-procedural specific details (e.g. complexity of 
lesions), which may have contributed to outcomes.
All NSTEMI patients All NSTEMI patients discharged alive
Death during 
hospitalization
Death within 30 days 
from MI onset
Death within 1 year 
from MI onset
Rehospitalization for HF 
within 1 year from MI 
discharge
Rehospitalization for 
MI within 1 year from 
MI discharge
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Unadjusted
HDL-C in mmol/l 0.78 (0.42–1.44) 0.426 0.90 (0.50–1.62) 0.728 1.26 (1.00–1.58) 0.046 1.14 (0.93–1.39) 0.218 1.23 (0.83–1.81) 0.304
Ordinal categories
>=1.6 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
1.0–1.5 1.75 (0.63–4.85) 0.284 1.16 (0.46–2.89) 0.752 0.78 (0.50–1.23) 0.290 0.98 (0.53–1.82) 0.952 1.10 (0.58–2.11) 0.766
<1.0 1.53 (0.55–4.27) 0.415 1.08 (0.43–2.71) 0.868 0.79 (0.50–1.25) 0.313 0.75 (0.40–1.40) 0.371 0.97 (0.51–1.86) 0.935
Adjusted*
HDL-C in mmol/l 0.61 (0.26–1.39) 0.236 0.68 (0.33–1.37) 0.276 0.94 (0.69–1.28) 0.700 1.06 (0.81–1.38) 0.672 1.33 (1.12–1.58) 0.001
Ordinal categories
>=1.6 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
1.0–1.5 6.57 (0.88–48.84) 0.066 3.51 (0.84–14.68) 0.086 1.54 (0.84–2.83) 0.159 1.41 (0.62–3.21) 0.411 1.08 (0.48–2.47) 0.846
<1.0 5.42 (0.73–40.54) 0.099 3.27 (0.77–13.84) 0.107 1.64 (0.89–3.03) 0.112 1.15 (0.50–2.63) 0.741 1.01 (0.44–2.35) 0.978
Table 4. Unadjusted and adjusted analysis examining the correlations between high density lipoprotein 
cholesterol levels and the primary and secondary outcomes in non-ST elevation myocardial infarction patients 
who underwent percutaneous coronary intervention. *Adjusted for: oral medication for hyperlipidemia 
(yes/no/not applicable), age (numeric), sex (male/female), race (chinese/malay/indian/others), history of 
diabetes (yes/no), history of hypertension (yes/no), smoking status (never/former/current), history of AMI/
CABG/PTCA (yes/no), BMI (numeric), Killip class on admission (1/2/3/4), CPR in ambulance/ED (yes/no), 
random blood glucose within 72 h from onset (numeric), creatinine on admission (numeric), haemoglobin 
on admission (numeric), elevated first troponin within 72 h from MI onset (yes/no), left ventricular ejection 
fraction <50% during hospitalization (yes/no).
Death during 
hospitalization
Death within 30 
days from MI onset
Death within 1 
year from MI onset
Rehospitalization 
for HF within 1 year 
from MI discharge
Rehospitalization 
for MI within 1 year 
from MI discharge
LDL-C
Unadjusted 0.400 0.317 0.001 0.056 0.495
Adjusted* 0.506 0.951 0.209 0.194 0.109
TG
Unadjusted 0.910 0.612 0.948 0.158 0.042
Adjusted8 0.731 0.942 0.893 0.211 0.244
TC
Unadjusted 0.081 0.026 <0.001 0.018 0.448
Adjusted* 0.401 0.589 0.111 0.148 0.215
HDL-C
Unadjusted 0.034 0.057 0.040 0.333 0.694
Adjusted* 0.015 0.081 0.060 0.635 0.604
Table 5. P value for interaction between type of myocardial infarction and lipids. *Adjusted for: oral 
medication for hyperlipidemia (yes/no/not applicable), age (numeric), sex (male/female), race (chinese/malay/
indian/others), history of diabetes (yes/no), history of hypertension (yes/no), smoking status (never/former/
current), history of AMI/CABG/PTCA (yes/no), BMI (numeric), Killip class on admission (1/2/3/4), CPR in 
ambulance/ED (yes/no), random blood glucose within 72 h from onset (numeric), creatinine on admission 
(numeric), haemoglobin on admission (numeric), elevated first troponin within 72 h from MI onset (yes/no), 
left ventricular ejection fraction <50% during hospitalization (yes/no). Abbreviations: HDL-C, high density 
lipoprotein cholesterol; HF, heart failure; LDL-C, low density lipoprotein cholesterol; MI, myocardial infarction; 
TC, total cholesterol; TG, triglycerides.
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conclusion
The lipid paradox appears to exist for LDL-C and TC levels and outcomes of death during hospitalization, 
death at 30 days and death at 1 year for STEMI patients. In the NSTEMI patients there appears to be a lipid 
pseudo-paradox. There is a significant interaction between HDL-C, the type of myocardial infarction and the 
outcome of death during hospitalization. These observations deserve further investigation.
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